Gene Therapy for High Grade Glioma: The Clinical Experience. (1st February 2023)

• Record Type: Journal Article
• Authors: Varela, Maria Luisa; Comba, Andrea; Faisal, Syed M; Argento, Anna; Franson, Andrea; Barissi, Marcus N; Sachdev, Sean; Castro, Maria G; Lowenstein, Pedro R
• Is Part Of: Expert opinion on biological therapy. Volume 23:Number 2(2023)
• Page Start: 145
• Page End: 161
• Publication Date: 2023-02-01
• Subjects: Gene therapy -- viral vectors -- glioblastoma -- high-grade glioma; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2022.2157718
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction: High-grade gliomas (HGG) are the most common malignant primary brain tumors in adults, with a median survival of ~18 months. The standard of care (SOC) is maximal safe surgical resection, and radiation therapy with concurrent and adjuvant temozolomide. This protocol remains unchanged since 2005, even though HGG median survival has marginally improved. Areas covered: Gene therapy was developed as a promising approach to treat HGG. Here, we review completed and ongoing clinical trials employing viral and non-viral vectors for adult and pediatric HGG, as well as the key supporting preclinical data. Expert opinion: These therapies have proven safe, and pre- and post-treatment tissue analyses demonstrated tumor cell lysis, increased immune cell infiltration, and increased systemic immune function. Although viral therapy in clinical trials has not yet significantly extended the survival of HGG, promising strategies are being tested. Oncolytic HSV vectors have shown promising results for both adult and pediatric HGG. A recently published study demonstrated that HG47Δ improved survival in recurrent HGG. Likewise, PVSRIPO has shown survival improvement compared to historical controls. It is likely that further analysis of these trials will stimulate the development of new administration protocols, and new therapeutic combinations that will improve HGG prognosis.